BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

L Robertson, H Hanson, S Seal, M Warren-Perry, D Hughes, I Howell, C Turnbull, R Houlston, S Shanley, S Butler, D G Evans, G Ross, D Eccles, A Tutt, N Rahman, TNT Trial TMG, Zosia Miedzybrodzka

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background:

Triple-negative (TN) tumours are the predominant breast cancer subtype in BRCA1 mutation carriers. Recently, it was proposed that all individuals below 50 years of age with TN breast cancer should be offered BRCA testing. We have evaluated the BRCA1 mutation frequency and the implications for clinical practice of undertaking genetic testing in women with TN breast cancer.


Methods:

We undertook BRCA1 mutation analysis in 308 individuals with TN breast cancer, 159 individuals from unselected series of breast cancer and 149 individuals from series ascertained on the basis of young age and/or family history.


Results:

BRCA1 mutations were present in 45 out of 308 individuals. Individuals with TN cancer <50 years had >10% likelihood of carrying a BRCA1 mutation in both the unselected (11 out of 58, 19%) and selected (26 out of 111, 23%) series. However, over a third would not have been offered testing using existing criteria. We estimate that testing all individuals with TN breast cancer <50 years would generate an extra 1200 tests annually in England.


Conclusion:

Women with TN breast cancer diagnosed below 50 years have >10% likelihood of carrying a BRCA1 mutation and are therefore eligible for testing in most centres. However, implementation may place short-term logistical and financial burdens on genetic services.
Original languageEnglish
Pages (from-to)1234-1238
Number of pages5
JournalBritish Journal of Cancer
Volume106
Issue number6
DOIs
Publication statusPublished - 13 Mar 2012

Fingerprint

Triple Negative Breast Neoplasms
Mutation
Genetic Services
Breast Neoplasms
Genetic Testing
Mutation Rate
Neoplasms

Cite this

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. / Robertson, L; Hanson, H; Seal, S; Warren-Perry, M; Hughes, D; Howell, I; Turnbull, C; Houlston, R; Shanley, S; Butler, S; Evans, D G; Ross, G; Eccles, D; Tutt, A; Rahman, N; TNT Trial TMG ; Miedzybrodzka, Zosia.

In: British Journal of Cancer, Vol. 106, No. 6, 13.03.2012, p. 1234-1238.

Research output: Contribution to journalArticle

Robertson, L, Hanson, H, Seal, S, Warren-Perry, M, Hughes, D, Howell, I, Turnbull, C, Houlston, R, Shanley, S, Butler, S, Evans, DG, Ross, G, Eccles, D, Tutt, A, Rahman, N, TNT Trial TMG & Miedzybrodzka, Z 2012, 'BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years', British Journal of Cancer, vol. 106, no. 6, pp. 1234-1238. https://doi.org/10.1038/bjc.2012.31
Robertson, L ; Hanson, H ; Seal, S ; Warren-Perry, M ; Hughes, D ; Howell, I ; Turnbull, C ; Houlston, R ; Shanley, S ; Butler, S ; Evans, D G ; Ross, G ; Eccles, D ; Tutt, A ; Rahman, N ; TNT Trial TMG ; Miedzybrodzka, Zosia. / BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. In: British Journal of Cancer. 2012 ; Vol. 106, No. 6. pp. 1234-1238.
@article{7905b8f3821947fca00b9285e7b69930,
title = "BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years",
abstract = "Background:Triple-negative (TN) tumours are the predominant breast cancer subtype in BRCA1 mutation carriers. Recently, it was proposed that all individuals below 50 years of age with TN breast cancer should be offered BRCA testing. We have evaluated the BRCA1 mutation frequency and the implications for clinical practice of undertaking genetic testing in women with TN breast cancer.Methods:We undertook BRCA1 mutation analysis in 308 individuals with TN breast cancer, 159 individuals from unselected series of breast cancer and 149 individuals from series ascertained on the basis of young age and/or family history.Results:BRCA1 mutations were present in 45 out of 308 individuals. Individuals with TN cancer <50 years had >10{\%} likelihood of carrying a BRCA1 mutation in both the unselected (11 out of 58, 19{\%}) and selected (26 out of 111, 23{\%}) series. However, over a third would not have been offered testing using existing criteria. We estimate that testing all individuals with TN breast cancer <50 years would generate an extra 1200 tests annually in England.Conclusion:Women with TN breast cancer diagnosed below 50 years have >10{\%} likelihood of carrying a BRCA1 mutation and are therefore eligible for testing in most centres. However, implementation may place short-term logistical and financial burdens on genetic services.",
author = "L Robertson and H Hanson and S Seal and M Warren-Perry and D Hughes and I Howell and C Turnbull and R Houlston and S Shanley and S Butler and Evans, {D G} and G Ross and D Eccles and A Tutt and N Rahman and {TNT Trial TMG} and Zosia Miedzybrodzka",
year = "2012",
month = "3",
day = "13",
doi = "10.1038/bjc.2012.31",
language = "English",
volume = "106",
pages = "1234--1238",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

AU - Robertson, L

AU - Hanson, H

AU - Seal, S

AU - Warren-Perry, M

AU - Hughes, D

AU - Howell, I

AU - Turnbull, C

AU - Houlston, R

AU - Shanley, S

AU - Butler, S

AU - Evans, D G

AU - Ross, G

AU - Eccles, D

AU - Tutt, A

AU - Rahman, N

AU - TNT Trial TMG

AU - Miedzybrodzka, Zosia

PY - 2012/3/13

Y1 - 2012/3/13

N2 - Background:Triple-negative (TN) tumours are the predominant breast cancer subtype in BRCA1 mutation carriers. Recently, it was proposed that all individuals below 50 years of age with TN breast cancer should be offered BRCA testing. We have evaluated the BRCA1 mutation frequency and the implications for clinical practice of undertaking genetic testing in women with TN breast cancer.Methods:We undertook BRCA1 mutation analysis in 308 individuals with TN breast cancer, 159 individuals from unselected series of breast cancer and 149 individuals from series ascertained on the basis of young age and/or family history.Results:BRCA1 mutations were present in 45 out of 308 individuals. Individuals with TN cancer <50 years had >10% likelihood of carrying a BRCA1 mutation in both the unselected (11 out of 58, 19%) and selected (26 out of 111, 23%) series. However, over a third would not have been offered testing using existing criteria. We estimate that testing all individuals with TN breast cancer <50 years would generate an extra 1200 tests annually in England.Conclusion:Women with TN breast cancer diagnosed below 50 years have >10% likelihood of carrying a BRCA1 mutation and are therefore eligible for testing in most centres. However, implementation may place short-term logistical and financial burdens on genetic services.

AB - Background:Triple-negative (TN) tumours are the predominant breast cancer subtype in BRCA1 mutation carriers. Recently, it was proposed that all individuals below 50 years of age with TN breast cancer should be offered BRCA testing. We have evaluated the BRCA1 mutation frequency and the implications for clinical practice of undertaking genetic testing in women with TN breast cancer.Methods:We undertook BRCA1 mutation analysis in 308 individuals with TN breast cancer, 159 individuals from unselected series of breast cancer and 149 individuals from series ascertained on the basis of young age and/or family history.Results:BRCA1 mutations were present in 45 out of 308 individuals. Individuals with TN cancer <50 years had >10% likelihood of carrying a BRCA1 mutation in both the unselected (11 out of 58, 19%) and selected (26 out of 111, 23%) series. However, over a third would not have been offered testing using existing criteria. We estimate that testing all individuals with TN breast cancer <50 years would generate an extra 1200 tests annually in England.Conclusion:Women with TN breast cancer diagnosed below 50 years have >10% likelihood of carrying a BRCA1 mutation and are therefore eligible for testing in most centres. However, implementation may place short-term logistical and financial burdens on genetic services.

U2 - 10.1038/bjc.2012.31

DO - 10.1038/bjc.2012.31

M3 - Article

VL - 106

SP - 1234

EP - 1238

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 6

ER -